Lyell Immunopharma (LYEL) Gains from Investment Securities (2020 - 2024)
Lyell Immunopharma recorded quarterly Gains from Investment Securities of -$12.9 million in Q4 2024, down 17106.58% quarter-over-quarter from $76000.0 in Q1 2024, and down 10608.13% year-over-year from N/an in Q1 2024.
Lyell Immunopharma's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$12.9 million for Q4 2024.
- In Q4 2024, Gains from Investment Securities fell 10608.13% year-over-year to -$12.9 million; the TTM figure through Mar 2026 stood at -$12.9 million (changed N/A YoY), while the FY2025 annual figure was $1000.0, down 98.68% from the prior year.
- Gains from Investment Securities came in at -$12.9 million for Q4 2024 at Lyell Immunopharma, down from $76000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $42.2 million in Q2 2021 to a low of -$12.9 million in Q4 2024.
- A 5-year average of $10.2 million and a median of $3.8 million in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 10.14% in 2024 and fell as far as 10608.13% in 2024.
- Lyell Immunopharma's Gains from Investment Securities stood at $31.8 million in 2020, then grew by 14.47% to $36.4 million in 2021, then sank by 87.27% to $4.6 million in 2022, then plunged by 97.35% to $123000.0 in 2023, then slumped by 10608.13% to -$12.9 million in 2024.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$12.9 million, $76000.0, and $123000.0 for Q4 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -12.93 Mn |
| Dec 31, 2024 | -12.93 Mn |
| Mar 31, 2024 | 76,000.00 |
| Mar 31, 2024 | 76,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Jun 30, 2023 | 2.92 Mn |
| Jun 30, 2023 | 2.92 Mn |
| Mar 31, 2023 | 69,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 4.63 Mn |
| Dec 31, 2022 | 4.63 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Dec 31, 2021 | 36.40 Mn |
| Dec 31, 2021 | 36.40 Mn |
| Sep 30, 2021 | 12.52 Mn |
| Sep 30, 2021 | 12.52 Mn |
| Jun 30, 2021 | 42.18 Mn |
| Jun 30, 2021 | 42.18 Mn |
| Mar 31, 2021 | 43,000.00 |
| Mar 31, 2021 | 43,000.00 |
| Sep 30, 2020 | 31.80 Mn |
| Sep 30, 2020 | 31.80 Mn |